INCAGN 1876

Drug Profile

INCAGN 1876

Alternative Names: Anti-GITR-agonist-antibody-Incyte; INCAGN 01876; INCAGN-1876

Latest Information Update: 28 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator 4-Antibody; Ludwig Institute for Cancer Research
  • Developer Agenus; Incyte Corporation; Ludwig Institute for Cancer Research
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action TNFRSF18 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Preclinical Cancer

Most Recent Events

  • 13 Sep 2017 Incyte Corporation plans a phase I/II trial for Cancer (Metastatic disease, Late-stage disease) in USA (NCT03277352)
  • 13 Apr 2017 Phase-I/II clinical trials in Solid tumours (Metastatic disease, Second-line therapy or greater, Late-stage disease) in USA (IV) (NCT03126110)
  • 14 Feb 2017 Incyte and Agenus amend licensing agreement from profit-sharing agreement to royalty bearing agreement
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top